Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1995
Quantitation of the renal clearance of interleukin-2 using nephrectomized and ureter-ligated ratsJ A Gibbons, Z P Luo, E R Hannon, et al.
Clinical Pharmacokinetics|January 1, 1995
The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridineW M Awni, R A Braeckman, C S Locke, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 29, 1999
Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distributionR J Laham, M Rezaee, M Post, et al.
Clinical Pharmacokinetics|January 1, 1995
The pharmacokinetics of zileuton in healthy young and elderly volunteersR A Braeckman, G R Granneman, C S Locke, et al.
Clinical Pharmacokinetics|January 1, 1995
Effect of zileuton on theophylline pharmacokineticsG R Granneman, R A Braeckman, C S Locke, et al.
Clinical Pharmacology and Therapeutics|March 1, 1995
The effect of zileuton on antipyrine and indocyanine green dispositionJ V St Peter, R A Braeckman, G R Granneman, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 29, 2000
Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigsS A Chen, R J Sawchuk, R C Brundage, et al.
Clinical Pharmacokinetics|January 1, 1995
The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileutonW M Awni, J H Cavanaugh, R A Braeckman, et al.
Clinical Pharmacokinetics|January 1, 1995
The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteersW M Awni, R A Braeckman, J H Cavanaugh, et al.
Clinical Pharmacology and Therapeutics|May 29, 2000
The influence of reduced liver blood flow on the pharmacokinetics and pharmacodynamics of recombinant tissue factor pathway inhibitorM J Kemme, J Burggraaf, R C Schoemaker, et al.
Pageof 3